JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States

Inflammatory breast cancer (IBC) is a difficult-to-treat disease with poor clinical outcomes due to high risk of metastasis and resistance to treatment. In breast cancer, CD44(+)CD24(-) cells possess stem cell-like features and contribute to disease progression, and we previously described a CD44(+)CD24(-)pSTAT3(+) breast cancer cell subpopulation that is dependent on JAK2/STAT3 signaling. Here we report that CD44(+)CD24(-) cells are the most frequent cell type in IBC and are commonly pSTAT3(+). Combination of JAK2/STAT3 inhibition with paclitaxel decreased IBC xenograft growth more than either agent alone. IBC cell lines resistant to paclitaxel and doxorubicin were developed and characterized to mimic therapeutic resistance in patients. Multi-omic profiling of parental and resistant cells revealed enrichment of genes associated with lineage identity and inflammation in chemotherapy-resistant derivatives. Integrated pSTAT3 chromatin immunoprecipitation sequencing and RNA sequencing (RNA-seq) analyses showed pSTAT3 regulates genes related to inflammation and epithelial-to-mesenchymal transition (EMT) in resistant cells, as well as PDE4A, a cAMP-specific phosphodiesterase. Metabolomic charac-terization identified elevated cAMP signaling and CREB as a candidate therapeutic target in IBC. Investigation of cellular dynamics and heterogeneity at the single cell level during chemotherapy and acquired resistance by CyTOF and single cell RNA-seq identified mechanisms of resistance including a shift from luminal to basal/mesenchymal cell states through selection for rare preexisting subpopulations or an acquired change. Finally, combination treatment with paclitaxel and JAK2/STAT3 inhibition prevented the emergence of the mesenchymal chemo-resistant subpopulation. These results provide mechanistic rational for combination of chemotherapy with inhibition of JAK2/ STAT3 signaling as a more effective therapeutic strategy in IBC.Significance: Chemotherapy resistance in inflammatory breast cancer is driven by the JAK2/STAT3 pathway, in part via cAMP/ PKA signaling and a cell state switch, which can be overcome using paclitaxel combined with JAK2 inhibitors.

Automated summary

Inflammatory breast cancer (IBC) is a difficult-to-treat disease with poor clinical outcomes due to high risk of metastasis and resistance to treatment. CD44(+)CD24(-) cells, which possess stem cell-like features, are the most frequent cell type in IBC and are commonly activated by the JAK2/STAT3 signaling pathway. Combination therapy with JAK2/STAT3 inhibition and paclitaxel has shown promising results in decreasing IBC xenograft growth. Furthermore, single-cell analyses have revealed the mechanisms of chemotherapy resistance and the potential of targeting the cAMP/PKA signaling pathway in IBC.